

T: 0131-244 2528 0131-244 2375  
E: irene.fazakerley@scotland.gsi.gov.uk  
9 February 2012

IMMEDIATE MESSAGE TO:

1. Directors of Pharmacy
2. Chief Pharmacists NHS Boards
3. Hospital Pharmacy Managers
4. Medical Directors NHS Boards
5. Chief Executives NHS Boards

Dear Healthcare Professional,

**DRUG ALERT CLASS 3 NO 6 - IMMEDIATE**

Please see the attached drug safety information for onward transmission as below.  
Please could all Directors of Pharmacy forward this alert to:-

- Community Pharmacists
- Hospital Pharmacists
- Chief Pharmacists to forward on to Medicines Information Pharmacists

1. Please could Medical Directors forward this alert to:-

- General Practitioners
- Accident & Emergency Departments
- Directors of Public Health
- Relevant Clinics
- Chief Executives of NHS Board

Thank you for your co-operation.

Yours sincerely

**IRENE FAZAKERLEY**  
**Pharmacy and Medicines Division**

Safeguarding public health  
Defective Medicines Report Centre  
151 Buckingham Palace Road  
London  
SW1W 9SZ  
Telephone +44 (0)20 3080 6574



MHRA

# DRUG ALERT

## CLASS 3 MEDICINES RECALL

Action Within 5 Days  
PHARMACY LEVEL RECALL

Date: 09 February 2012

EL (12)A/06

Our Ref: MDR 29-01/12

Dear Healthcare Professional,

### TEVA UK LIMITED

#### Alendronic Acid 10mg Tablets

PL 00289/0703

Batch Number	Expiry Date	Pack Size	First Distributed
006829	Mar 2014	1 x 28	23 May 2011

Teva UK Limited is recalling the above batch because, during non-routine testing 10 months after manufacture, some samples were found to be marginally out of specification for assay. This finding is not expected to impact on patient safety at this stage but there are concerns about potential effects on potency of the batch during the remainder of the shelf-life.

Remaining stocks of this batch should be returned to the original wholesaler for credit. For further stock enquiries please contact Teva UK Customer Liaison Team on 0800 590502

For medical information enquiries please contact Teva UK Limited by phone on 0207 5407117 or by email at [medinfo@tevauk.com](mailto:medinfo@tevauk.com).

Recipients of this Drug Alert should bring it to the attention of relevant contacts by copy of this letter. Primary Care Trusts are asked to forward this to relevant clinics and to General Practitioners and Community Pharmacists for information.

Yours faithfully

Alison Bunce

Pharmaceutical Assessor, DMRC

#### MHRA Distribution:

Regional Contacts for NHS Trusts and Provider Units

Chief Pharmacists: England, Scotland, Wales, Northern Ireland

Prison Health Policy Unit (DH)

Chief Pharmacists: Jersey, Guernsey, Alderney, Sark, Isle of Man, Gibraltar

Special Hospitals

Healthcare Commission for distribution to Independent Health Care Establishments

Primary Care Trusts (England)

Medicines and Healthcare products Regulatory Agency (MHRA)

151 Buckingham Palace Road London SW1W 9SZ UK

T 020 3080 6000 [www.mhra.gov.uk](http://www.mhra.gov.uk)

An executive agency of the Department of Health